Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BLTE Belite Bio, Inc.

Closed President's Day 02-13 16:00:00 EST

175.26

+0.65

+0.37%

盘后175.26

+0.000.00%

16:10 EST

High177.22	Low171.35	Vol118.30K
Open177.22	D1 Closing174.61	Amplitude3.36%
Mkt Cap6.57B	Tradable Cap3.50B	Total Shares37.51M
T/O20.66M	T/O Rate0.59%	Tradable Shares19.96M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BLTE","market":"US","secType":"STK","nameCN":"Belite Bio, Inc.","latestPrice":175.26,"timestamp":1771016400000,"preClose":174.61,"halted":0,"volume":118299,"hourTrading":{"tag":"盘后","latestPrice":175.26,"preClose":175.26,"latestTime":"16:10 EST","volume":338,"amount":59237.88,"timestamp":1771017004699,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.003722581753622228,"floatShares":19963600,"shares":37514630,"eps":-1.929025,"marketStatus":"Closed President's Day","change":0.65,"latestTime":"02-13 16:00:00 EST","open":177.22,"high":177.22,"low":171.35,"amount":20660003.0676,"amplitude":0.033618,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.929025,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1651204800000,"exchange":"NASDAQ","adjPreClose":174.61,"preHourTrading":{"tag":"盘前","latestPrice":177.7,"preClose":174.61,"latestTime":"08:41 EST","volume":110,"amount":19526.0208,"timestamp":1770990060610,"change":3.09,"changeRate":0.017697,"amplitude":0.017181},"postHourTrading":{"tag":"盘后","latestPrice":175.26,"preClose":175.26,"latestTime":"16:10 EST","volume":338,"amount":59237.88,"timestamp":1771017004699,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6661444823480499},"requestUrl":"/m/hq/s/BLTE","defaultTab":"news","newsList":[{"id":"2608353828","title":"Belite Bio (BLTE) Valuation Check As Phase 3 DRAGON Tinlarebant Data Presentations Approach","url":"https://stock-news.laohu8.com/highlight/detail?id=2608353828","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608353828?lang=en_us&edition=fundamental","pubTime":"2026-02-02 04:13","pubTimestamp":1769976815,"startTime":"0","endTime":"0","summary":"Belite Bio (BLTE) is back in focus after confirming it will present topline Phase 3 DRAGON data for tinlarebant in adolescent Stargardt disease at the upcoming Asia Pacific Academy of Ophthalmology Congress.\nSee our latest analysis for Belite Bio.\nThose DRAGON data presentations come after a strong run in the stock, with a 90 day share price return of 50.36% and a 1 year total shareholder return of 191.18%, suggesting momentum has been building around the story.\nIf you are watching how...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/belite-bio-blte-valuation-check-as-phase-3-dragon-tinlareban","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-blte/belite-bio/news/belite-bio-blte-valuation-check-as-phase-3-dragon-tinlareban","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","DCF","BLTE"],"gpt_icon":0},{"id":"2607087988","title":"Belite Bio Showcases Phase 3 Tinlarebant Results at Asia-Pacific Academy of Ophthalmology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2607087988","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607087988?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:00","pubTimestamp":1769691618,"startTime":"0","endTime":"0","summary":"Belite Bio Inc. will participate in the Asia-Pacific Academy of Ophthalmology  2026 Congress, taking place from February 5-7, 2026, in Hong Kong. The company will present previously disclosed topline results from the Phase 3 DRAGON study of tinlarebant in adolescents with Stargardt disease type 1 , host an oral presentation on February 6, and sponsor a lunch symposium on February 7. An exhibition booth will also be featured throughout the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via GlobeNewswire  on January 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDLb5QcZ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","SG9999014013.SGD","BK4588","BK4585","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","LU2210149790.SGD","NDAQ","BLTE","IE00BKPKM429.USD","LU0314104364.USD","LU2210150020.SGD","LU2095319765.USD","SG9999014021.USD","BK4007"],"gpt_icon":0},{"id":"2606794143","title":"Belite Bio Price Target Maintained With a $185.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2606794143","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606794143?lang=en_us&edition=fundamental","pubTime":"2026-01-28 17:55","pubTimestamp":1769594100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLTE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 04:55 ET (09:55 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2606798840","title":"U.S. RESEARCH ROUNDUP- Boeing, Carvana, UnitedHealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2606798840","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606798840?lang=en_us&edition=fundamental","pubTime":"2026-01-28 15:23","pubTimestamp":1769584984,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Boeing, Carvana, UnitedHealthJan 28 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Boeing, Carva","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nL4N3YT0MZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVA","GM","AXSM","IE00B775SV38.USD","AAL","CCBG","BLTE","AFL","NNE","GGG","BA","BRBR","BK4545","NEE","NXT","BJ","BK4162","EIX","ENVA","HAL","BRO","HL","DTE","IE00BJJMRZ35.SGD","FFIV","GLW","BK4187","CMS","JBLU","LNG","LU1621767810.EUR","SMR","BMY","CVLT","CHMG","CVNA","HCA","IE00BLSP4239.USD","MANH","OKLO","BIRK","ALB","BANR","CHD","PCG","NOC","BKR","IDA","LU2242652126.USD"],"gpt_icon":1},{"id":"2606734399","title":"H.C. Wainwright Remains a Buy on Belite Bio, Inc. ADR (BLTE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606734399","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606734399?lang=en_us&edition=fundamental","pubTime":"2026-01-28 01:45","pubTimestamp":1769535919,"startTime":"0","endTime":"0","summary":"In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Belite Bio, Inc. ADR, with a price target of $185.00. According...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-belite-bio-inc-adr-blte-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-belite-bio-inc-adr-blte-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2606378467","title":"Belite Bio Completes Enrollment in the Dragon Ii Clinical Trial of Tinlarebant for Stargardt Disease (Stgd1)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606378467","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606378467?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA4CBKXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"2606106784","title":"Belite Bio Inc - to File Nda With FDA in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606106784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606106784?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518805,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA4CBKXY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2606782859","title":"Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606782859","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606782859?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518800,"startTime":"0","endTime":"0","summary":"Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal, global Phase 3 DRAGON trial with 36% reduction in ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/27/3226453/0/en/Belite-Bio-Completes-Enrollment-in-the-DRAGON-II-Clinical-Trial-of-Tinlarebant-for-Stargardt-Disease-STGD1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880398471.USD","AMDY","LU1803068979.SGD","BK4575","LU1988902786.USD","AMDW","BK4141","AMDG","LU0274383776.USD","LU1242518931.SGD","BK4566","BK4614","LU1880398554.USD","BK4605","LU1951200564.SGD","LU2098885051.SGD","BK4512","LU2250418816.HKD","LU0823434740.USD","BK4532","AMDD","LU0109392836.USD","LU1242518857.USD","AMDU","BK4554","LU2360106780.USD","LU0127658192.USD","LU1861558580.USD","LU2355687059.USD","IE00B5949003.HKD","AMYY","LU2458330243.SGD","LU0390134368.USD","LU0889565833.HKD","IE0009356076.USD","IE00BMPRXR70.SGD","BLTE","LU0642271901.SGD","IE00BMPRXN33.USD","LU1316542783.SGD","BK4007","BK4534","BK4612","LU0979878070.USD","LU1303367103.USD","BK4529","IE0004445239.USD","BK4585","LU2458330169.SGD","LU0056508442.USD","DAMD","LU1923623000.USD","AMUU","LU0823421416.USD","LU0082616367.USD","LU2054465674.USD","BK4543","LU0823434583.USD","LU0198837287.USD","LU1852331112.SGD","LU1861559042.SGD","LU0823421333.USD","LU0719512351.SGD","BK4573","LU0081259029.USD","BK4588","LU2931357623.SGD","LU2089985449.USD","LU1951198990.SGD","LU1064131342.USD","LU1989764664.SGD","LU2264538146.SGD"],"gpt_icon":1},{"id":"2606228193","title":"BUZZ-U.S. STOCKS ON THE MOVE-Apple, Belite Bio, Bank of Marin Bancorp","url":"https://stock-news.laohu8.com/highlight/detail?id=2606228193","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606228193?lang=en_us&edition=fundamental","pubTime":"2026-01-27 02:46","pubTimestamp":1769453186,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Apple, Belite Bio, Bank of Marin BancorpEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nL6N3YR0MP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0057025933.USD","SG9999004303.SGD","LU1551013342.USD","LU2463028550.USD","LU0868494617.USD","LU1894683264.USD","IE00B5949003.HKD","IE00BJJMRZ35.SGD","LU0061475181.USD","LU1934455863.HKD","BK4547","LU2462611646.USD","BK4563","BK4591","BK4588","IE00BK4W5L77.USD","LU2063271972.USD","LU2168564495.EUR","IE0034235295.USD","LU0742534661.SGD","LU0792757196.USD","LU0532188223.SGD","BK4539","LU0943347566.SGD","LU2381873111.SGD","LU1046421795.USD","LU0251142724.SGD","LU2756315318.SGD","IE00BN29S564.USD","LU1201861249.SGD","LU2125909759.SGD","LU2326559502.SGD","LU0289739343.SGD","BK4211","SG9999001424.SGD","IE00B1XK9C88.USD","IE000W1ABFV2.USD","LU2065171402.SGD","SG9999001135.SGD","LU2108987350.USD","LU2041044095.USD","IE000YTNTUN2.SGD","LU2237957811.SGD","IE0001KFT4U8.USD","LU1066051225.USD","LU2463526074.USD","SG9999013486.USD","BK4097","LU0345774391.USD","LU0310799852.SGD","LU1074936037.SGD","LU1244550577.SGD","HK0000914686.HKD","IE0034235303.USD","LU0251132253.USD","LU0070302665.USD","LU1623119135.USD","LU1983299162.USD","BK4512","SGXZ81514606.USD","LU0122376428.USD","GB00B4QBRK32.GBP","IE00B19Z3581.USD","LU1989772840.SGD","LU2097829019.USD","BK4550","IE00BFTCPJ56.SGD","LU1150488135.SGD","LU1839390173.USD","LU1935043536.SGD","LU2242649171.HKD","LU1064131342.USD","IE00BYXW3230.USD","LU0234570918.USD","LU1883866441.USD","LU2065169927.USD","LU1366192091.USD","IE00B2PGVK34.USD","IE00BJJMRY28.SGD","LU1923622291.USD","BK4108","LU0061474960.USD","IE00BFSS8Q28.SGD","LU1852331112.SGD","IE00BN0W2W23.USD","LU1267930227.SGD","LU2505996509.AUD","IE0002270589.USD","LU0130103400.USD","LU1506573853.SGD","LU1116320901.HKD","LU2430703178.SGD","SG9999014914.USD","LU2430703251.USD","LU1223083913.SGD","LU1868836591.USD","IE00BKDWB100.SGD","LU0472753341.HKD","LU1582987597.SGD","LU1670711040.USD","LU1582986433.USD","LU0878866978.SGD","LU0061474705.USD","HK0000306685.HKD","SG9999014567.USD","LU0300736492.USD","BK4515","LU1804176565.USD","BK4096","SG9999015341.SGD","LU2357305700.SGD","IE00B3CCJ633.GBP","LU0787776722.HKD","LU0211328371.USD","LU0075056555.USD","LU0823421416.USD","BK4592","LU0882574139.USD","LU2347655073.USD","GB00BDT5M118.USD","SG9999001440.SGD","LU0912757837.SGD","IE00B19Z8X17.USD","IE00BQXX3C00.GBP","BK4190","LU0130102774.USD","SG9999014906.USD","LU2461242641.AUD","BK4141","LU2750360641.GBP","LU1815336760.USD","HK0000320264.USD","LU2360106780.USD","LU1989772923.USD","LU1868836914.USD","LU2092937221.SGD","LU2357125470.USD","LU0788109394.HKD","LU0724617625.USD","LU0353189763.USD","LU1861559042.SGD","LU0957808578.USD","LU0320765059.SGD","LU0345768153.USD","LU2505996681.GBP","LU1303367103.USD","LU2506951792.HKD","LU2023250504.SGD","LU0256863902.USD","LU1642822529.SGD","IE00B19Z3B42.SGD","LU1291159041.SGD","LU0345769631.USD","BK4168","LU0082616367.USD","IE00BBT3K403.USD","IE00BQXX3F31.USD","LU1267930813.SGD","LU0081259029.USD","LU0965508806.USD","LU2242650005.HKD","LU2403377893.USD","LU1223082196.USD","LU0820561818.USD","LU0964807845.USD","LU1267930490.SGD","LU0726765562.USD","BK4116","LU0689626769.HKD","LU1674673428.USD","IE0004445015.USD","LU2404859741.USD","BK4201","IE00B3CCJ963.GBP","LU1868837136.USD","LU0251131958.USD","LU1084165304.USD","LU2129689605.HKD","BK4570","LU0719512351.SGD","LU0690374615.EUR","LU1791710400.SGD","LU0154236417.USD","LU0096362180.USD","LU1564329032.USD","LU1629891620.HKD","LU0154245756.USD","LU0256331488.USD","LU2471134952.CNY","IE00BJLML261.HKD","LU0683600562.USD","LU2054465674.USD","LU2471134879.HKD","LU0052756011.USD","LU2360107325.USD","LU1670628061.USD","LU0466842654.USD","LU2125154778.USD","LU2756315664.SGD","SG9999002414.USD","LU0612318971.USD","LU0708994859.HKD","LU2236285917.USD","LU0029864427.USD","LU0965509010.AUD","LU1153585028.USD","LU0157215616.USD","LU0690374961.EUR","BK4090","LU0069063385.USD","IE000M9KFDE8.USD","IE00BGHQF417.EUR",".IXIC","LU0868494708.USD","BK4008","LU0795875086.SGD","LU0861579265.USD","LU1674673691.USD","LU2065171311.SGD","LU0823421333.USD","SG9999014575.USD","BK4596","LU0198837287.USD","LU0476273544.USD","LU0289961442.SGD","LU0788108826.HKD","LU0314104364.USD","LU1935042488.USD","IE0034235188.USD","BK4165","BMRC","LU0433182093.SGD","BK4554","LU1732800096.USD","LU1914381329.SGD","BK4524","LU2237443549.SGD","LU1571399168.USD","LU1935042215.USD","IE0002141913.USD","IE00B775H168.HKD","SGXZ23171101.USD","LU0070217475.USD","LU2362541513.USD","IE00B775SV38.USD","LU0128525689.USD","LU0823414478.USD","LU2452424414.USD","LU0238689110.USD","IE00BD6J9T35.USD","LU0320765646.SGD","IE0009355771.USD","LU1992135399.USD","BK4602","BK4123","IE0005OL40V9.USD","LU1989764748.USD","LU0965509283.SGD","IE000ITXATA3.USD","LU0266512473.USD","LU1823568750.SGD","LU0498741114.HKD","LU2462157665.USD","LU1564329628.SGD","LU1301847155.USD","LU0505663152.USD","LU2129689431.USD","GB00B4LPDJ14.GBP","BK4094","IE00B5TLWC47.USD","LU0011850046.USD","BK4567","LU0820561909.HKD","LU2023250843.SGD","LU2237443622.USD","BK4587","LU0738911758.USD","LU2264538146.SGD","LU2125154935.USD","LU2247934214.USD","IE00BFXG0V08.USD","IE0009356076.USD","LU0498741890.SGD","LU0630314457.HKD","LU0823434740.USD","BK4533","LU2213496289.HKD","LU2361044949.HKD","LU0132412106.USD","BK4015","BK4006","SG9999000418.SGD","HK0000320223.HKD","LU0068578508.USD","LU1670710588.SGD","LU0203201768.USD","LU0648000940.SGD","LU2896262040.SGD","LU2286300806.USD","LU2404859667.USD","LU1066053197.SGD","BK4147","BK4084","LU1564329115.USD","LU0097036916.USD","BK4581","LU2092937148.SGD","LU0456855351.SGD","LU1489326972.SGD","LU1935042991.SGD","LU1699723380.USD","LU1280957306.USD","LU2095319765.USD","BK4534","LU2129689514.USD","LU2249611893.SGD","HK0000914660.USD","LU2065170008.USD","LU2045819591.USD","SG9999002620.SGD","LU0545039389.USD","LU0106261372.USD","LU0080751232.USD","LU1242518857.USD","IE00B2B36J28.USD","LU1232071149.USD","BK4159","LU0266512127.USD","LU0557290698.USD","LU2087621335.USD","SG9999014542.SGD","LU0210533765.USD","LU0077335932.USD","IE00B19Z9Z06.USD","LU0345781412.USD","LU2097344431.USD","LU0444971666.USD","LU2347655156.SGD","LU0072462426.USD","BK4230","LU0006306889.USD","BK4553","LU0215105999.USD","IE00BLSP4239.USD","IE00BWXC8680.SGD","LU1815333072.USD","MACW.SI","LU1670710661.SGD","LU2294711713.HKD","LU1582987324.SGD","LU0942090050.USD","LU0323591593.USD","LU2250418816.HKD","SG9999014898.SGD","LU1814569148.SGD","LU1974910355.USD","LU2750360997.AUD","LU2592432038.USD","IE00BFMHRM44.USD","LU0354030438.USD","IE0004091025.USD","LU0949170426.SGD","CORD","LU2498475776.HKD","LU1720051017.SGD","LU0353189680.USD","LU0053666078.USD","IE00BK4W5M84.HKD","LU0417517546.SGD","LU1267930730.SGD","SG9999002406.SGD","LU0642271901.SGD","IE00B3S45H60.SGD","LU0345768740.USD","LU1244550221.USD","LU1201861165.SGD","LU2361044865.SGD","LU0345770308.USD","LU1929549753.HKD","LU0444973449.USD","LU2764263203.CNY","SGXZ99366536.SGD","LU1935043023.USD","LU1868836757.USD","LU0788109477.HKD","LU2272731865.HKD","LU1119994496.HKD","LU2552382215.SGD","LU1035775433.USD","LU0965509101.SGD","LU1162221912.USD","LU1712237335.SGD","LU0979878070.USD","LU0672654240.SGD","LU0210528500.USD","LU0949170772.SGD","BK4573","IE00BGHQF524.EUR","BK4139","LU2023251221.USD","LU0256863811.USD","SG9999015945.SGD","LU1633808545.USD","IE00BZ9MQY76.HKD","LU2237443382.USD","LU2746668461.USD","LU0345769128.USD","LU0048584097.USD","CRWU","LU1366333091.USD","LU1720051108.HKD","LU2077746001.SGD","LU2860962120.EUR","LU1037948541.HKD","BK4576","LU0820562030.AUD","LU1988902786.USD","SG9999015952.SGD","BK4179","LU0265550359.USD","LU0648001328.SGD","LU1992135472.HKD","LU2237957902.USD","IE00BSNM7G36.USD","LU1861558580.USD","LU2125909916.SGD","BK4585","LU0079474960.USD","IE00B7KXQ091.USD","LU0441851309.USD","LU0050427557.USD","LU2089284900.SGD","LU2602419157.SGD","LU0786609619.USD","SG9999015358.SGD","LU0170899867.USD","LU0708995401.HKD","IE00B894F039.SGD","LU1917777945.USD","LU2210150020.SGD","LU0267386448.USD","SG9999001077.SGD","LU1894683348.USD","LU2471134523.USD","IE00B2Q91V27.USD","LU0203202063.USD","LU0314106906.USD","LU1429558221.USD","BK4527","LU0210637038.USD","LU0055631609.USD","LU2265009873.SGD","IE00BMPRXQ63.HKD","LU2473716301.USD","BK4213","IE00B19Z9505.USD","IE000KEQY171.SGD","LU0345774631.USD","LU0348723411.USD","LU1551013425.SGD","LU2083900584.USD","BK4501","LU0354030511.USD","LU0689472784.USD","BK4559","LU0072463663.USD","IE0009G5SDU7.USD","LU1267930573.SGD","LU0130517989.USD","LU2362541273.HKD","IE00B19Z9P08.USD","LU0210536198.USD","LU1691799644.USD","LU2133065610.SGD","LU2764263039.SGD","BK4507","BK4574","IE00BMPRXN33.USD","LU1037948897.HKD","LU1116320737.USD","LU0300736062.USD","LU1066051498.USD","IE00BDCRKT87.USD","LU2430703095.HKD","LU0889566641.SGD","HK0000306701.USD","LU0225283273.USD","LU0211327993.USD","IE00BYQQ9H92.USD","LU0784385170.HKD","LU2089283258.USD","LU0553294199.USD","BK4516","SG9999014880.SGD","IE0003U64NQ7.SGD","IE00B4JS1V06.HKD","LU0128525929.USD","AAPL","LU0784383803.USD","IE00BLSP4452.SGD","LU2417539215.USD","LU0109391861.USD","IE00BFSS7M15.SGD","LU2272731600.USD","LU0345780521.USD","IE00BKVL7J92.USD","LU0788109048.HKD","LU1732799900.SGD","LU2106854487.HKD","LU2028103732.USD","LU1235294995.USD","LU2237443465.HKD","BK4528","LU1066051811.HKD","LU2237443978.SGD","LU1564329461.SGD","LU2087625088.SGD","LU0203347892.USD","IE00BN8TJ469.HKD","LU2361045086.USD","IE00BQXX3D17.EUR","LU1496350171.SGD","LU1150488218.USD","LU0158827948.USD","LU0788109121.HKD","LU1023059493.AUD","LU0098860793.USD","LU2543165471.USD","LU2098885051.SGD","LU2362540622.SGD","IE00BN0W2T93.GBP","LU0612318385.USD","LU0203345920.USD","LU0310800379.SGD","LU1206712785.SGD","LU1496350502.SGD","LU2471134796.USD","LU0572108347.SGD","IE00BJTD4N35.SGD","LU0330918003.SGD","LU0511384066.AUD","LU0957791311.USD","IE00BJTD4V19.USD","LU0276348264.USD","LU1934455194.USD","SG9999015986.USD","BK4532","LU1223082519.USD","LU2125910500.SGD","LU1069344957.HKD","LU2458330169.SGD","IE00BJT1NW94.SGD","IE00BN0W2V16.EUR","BK4543","BK4182","BK4122","IE00BZ1G4Q59.USD","LU1989771016.USD","BK4598","LU0784384876.USD","IE00BFXG1179.USD","LU1548497426.USD","LU2317271919.USD","SG9999015978.USD","LU1697837992.HKD","SGXZ51526630.SGD","LU2191332357.HKD","LU0124676726.USD","LU1934455277.USD","LU2552382132.HKD","LU0310800965.SGD","LU0265550946.USD","SG9999002521.SGD","LU1206713676.USD","LU1861214812.USD","BK4017","LU0278409577.USD","LU1778281490.HKD","LU0127658192.USD","LU1989764664.SGD","LU0795875169.SGD","LU2023250330.USD","LU2322448957.HKD","LU0528227936.USD","LU2092627202.USD","LU2746668974.SGD","LU0456854461.SGD","IE00BDRTCR15.USD","LU2168564065.EUR","LU1003077747.HKD","LU1127390331.HKD","IE00B1BXHZ80.USD","LU0345780281.USD","LU2097344357.USD","SGXZ31699556.SGD","LU1718418525.SGD","LU1145028129.USD","LU0823434583.USD","LU2065731478.USD","CWVX","LU2487616109.SGD","CRWG","LU0496367417.USD","BK4023","LU1582986359.USD","LU0661504455.SGD","LU2456880835.USD","LU0342679015.USD","LU0654597011.USD","LU2210149790.SGD","LU0274383776.USD","LU0096364046.USD","BK4022","BK4210","LU0368265418.SGD","LU1261432733.SGD","LU2271345857.HKD","LU0724618789.USD","BK4575","LU0985489474.SGD","BK4170","LU1244550494.USD","LU1670627923.USD","LU2111349929.HKD","LU2168564222.USD","LU2168564149.EUR","SG9999013460.SGD","LU2237443895.HKD","LU0056508442.USD","LU0640476718.USD","SG9999018865.SGD","SG9999002604.SGD","BK4077","LU0320765489.SGD","LU0109392836.USD","LU1803068979.SGD","SG9999002679.SGD","SG9999017495.SGD","LU0784385840.USD","LU0477156953.USD","LU2420271590.USD","LU0494093205.USD","BLTE","IE00BMPRXR70.SGD","LU0345770993.USD","LU0149725797.USD","LU2720916845.USD","SG9999013478.USD","LU1791710582.SGD","BK4584","LU0308772762.SGD","BK4500","LU0889565833.HKD","LU2237438978.USD","SG9999001143.SGD","LU2322448791.USD","LU1242518931.SGD","LU1839511570.USD","LU2764262908.HKD","BK4579","LU2272731782.SGD","LU0823414551.USD","LU0154245673.USD","SGXZ58947870.SGD","LU0234572021.USD","LU0158827781.USD","LU0208291251.USD","LU2552382058.USD","LU0316494557.USD","BK4505","SG9999002232.USD","SG9999014559.SGD","IE00BZ199S13.USD","LU2168563687.JPY","LU1316542783.SGD","IE00B3SWFQ91.USD","SG9999006266.SGD","LU1430597077.USD","IE0004086264.USD","IE00BJJMRX11.SGD","LU1435385759.SGD","LU0345780950.USD","LU1868837300.USD","BK4571","LU0980610538.SGD","LU1670711123.USD","LU0048573561.USD","LU2360032135.SGD","LU2458330243.SGD","SG9999018857.SGD","BK4541","LU0368265764.SGD","LU0985320562.USD","IE00B19Z8W00.USD","SG9999002224.SGD","IE0004445239.USD","IE00B7SZLL34.SGD","BK4566","IE00B4YYXB79.USD","LU1861219969.SGD","LU0211331839.USD"],"gpt_icon":1},{"id":"2606154241","title":"BUZZ-Belite Bio climbs as BofA starts coverage with 'buy' rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2606154241","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606154241?lang=en_us&edition=fundamental","pubTime":"2026-01-26 23:23","pubTimestamp":1769441038,"startTime":"0","endTime":"0","summary":"BUZZ-Belite Bio climbs as BofA starts coverage with 'buy' rating** Shares of drug developer Belite Bio BLTE.O rise 5.5% to $173.58** Brokerage BofA Global Research initiates stock with \"buy\" rating and sets PT at $195** BLTE is developing an oral, once-daily drug tinlarebant, which \"could be the first therapy\" approved for Stargardt disease type 1, a rare genetic disease causing vision loss in children, BofA says ** Tinlarebant slowed the disease by cutting lesion growth by about 36% over two years compared with placebo in a late-stage trial, and it was generally safe with only mild eye-related side effects** Brokerage says experts expect tinlarebant to be widely used in mildtomoderate patients, around 70–80% of them, because there are no approved treatments for the condition** BofA estimates tinlarebant to generate about $3.4 bln in peak sales for STGD1 by 2037, assuming an annual price of roughly $350,000** However, brokerage notes the FDA could request more data from a second trial,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nL4N3YR1D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","LU0417517546.SGD","LU0203347892.USD","IE00B19Z3581.USD","LU2129689605.HKD","LU1267930227.SGD","BAC","LU0477156797.USD","BK4581","LU0149725797.USD","LU1035773651.USD","LU1069347547.HKD","LU0170899867.USD","LU0310800965.SGD","LU0980610538.SGD","LU1883839398.USD","LU1162221912.USD","LU0971096721.USD","LU0098860793.USD","LU0477156953.USD","LU1804176565.USD","LU1718418525.SGD","BK4559","LU0314106906.USD","LU0106831901.USD","BK4504","LU1894683348.USD","LU1201861165.SGD","IE00BLSP4452.SGD","IE00BBT3K403.USD","IE00BZ1G4Q59.USD","IE0001KFT4U8.USD","IE00BFXG1179.USD","BK4585","LU0128525689.USD","BLTE","IE00B1BXHZ80.USD","LU0320765646.SGD","LU0683600562.USD","LU1201861249.SGD","BK4007","LU0320765489.SGD","LU2133065610.SGD","LU0130103400.USD","LU0321505868.SGD","LU1668664300.SGD","LU1506573853.SGD","LU0306806265.USD","LU0640476718.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2606217199","title":"BofA Securities Initiates Coverage on Belite Bio With Buy Rating, $195 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2606217199","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606217199?lang=en_us&edition=fundamental","pubTime":"2026-01-26 20:16","pubTimestamp":1769429770,"startTime":"0","endTime":"0","summary":"BofA Securities Initiates Coverage on Belite Bio With Buy Rating, $195 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2606217340","title":"Belite Bio Inc : Bofa Global Research Initiates Coverage With  Buy Rating and Price Objective $195.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2606217340","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606217340?lang=en_us&edition=fundamental","pubTime":"2026-01-26 20:07","pubTimestamp":1769429238,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YR0KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"2606217308","title":"Belite Bio Initiated at Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2606217308","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606217308?lang=en_us&edition=fundamental","pubTime":"2026-01-26 20:07","pubTimestamp":1769429220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLTE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 26, 2026 07:07 ET (12:07 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"2606851292","title":"U.S. RESEARCH ROUNDUP-CACI International, First Citizens Bancshares, Teledyne Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2606851292","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606851292?lang=en_us&edition=fundamental","pubTime":"2026-01-26 15:22","pubTimestamp":1769412133,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-CACI International, First Citizens Bancshares, Teledyne TechnologiesJan 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-lis","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nL4N3YR0FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BKR","AMUU","AMDY","AMDD","CAT","COHR","ASB","CMI","BE","AMDL","CTBI","ACM","CACI","CADE","AMDW","T","AAPL","COHU","CTSH","CSCO","AMGN","AMD","APP","AMDU","FIX","ALK","USAW.SI","BLTE","BRBR","AMDG","LNG","ADBE","BANR","BAH","BOKF","COF","AMAL","CWAN","AMYY","BMY","SRCE","AMZN","CNK","ALLY","ALB","CFG","DAMD","COMP","EAT","MO"],"gpt_icon":1},{"id":"2605489377","title":"Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Arrowhead Pharmaceuticals (ARWR) and Alector (ALEC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605489377","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605489377?lang=en_us&edition=fundamental","pubTime":"2026-01-21 23:50","pubTimestamp":1769010619,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Belite Bio, Inc. ADR (BLTE – Research Report), Arrow...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-arrowhead-pharmaceuticals-arwr-and-alector-alec-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-arrowhead-pharmaceuticals-arwr-and-alector-alec-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BLTE","ALEC","XBI","XLV","BK4139","ARWR","BK4585","LABU","BK4581","LU0128526141.USD","BK4137","BK4588","HCSG","BK4007"],"gpt_icon":0},{"id":"2601532819","title":"Belite Bio Initiated at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2601532819","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601532819?lang=en_us&edition=fundamental","pubTime":"2026-01-06 23:56","pubTimestamp":1767714960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BLTE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 10:56 ET (15:56 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BLTE"],"gpt_icon":0},{"id":"2601161118","title":"Belite Bio Inc : Morgan Stanley Initiates Coverage With Overweight Rating; Price Target $191","url":"https://stock-news.laohu8.com/highlight/detail?id=2601161118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601161118?lang=en_us&edition=fundamental","pubTime":"2026-01-06 23:31","pubTimestamp":1767713473,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y710Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2601547891","title":"Morgan Stanley Initiates Belite Bio at Overweight With $191 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2601547891","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601547891?lang=en_us&edition=fundamental","pubTime":"2026-01-06 19:39","pubTimestamp":1767699547,"startTime":"0","endTime":"0","summary":"Belite Bio's (BLTE) US stock has an average rating of buy and mean price target of $184.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BLTE","BK4007"],"gpt_icon":0},{"id":"2601086401","title":"U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure","url":"https://stock-news.laohu8.com/highlight/detail?id=2601086401","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601086401?lang=en_us&edition=fundamental","pubTime":"2026-01-06 15:53","pubTimestamp":1767686032,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR InfrastructureJan 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nL8N3Y7095:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM","BALL","IE00B5TLWC47.USD","AAL","ALK","BLTE","BIIB","LU2125154935.USD","APGE","BA","AVY","ALGT","BBBY","BK4532","BAC","ALNY","WMS","BBIO","SG9999014005.SGD","AGNC","AMT","DRUG","BK4135","SGXZ23171101.USD","ALL","AJG","ACAD","BP","BKD","ADAM","LU0757428866.USD","ALHC","BMY","LU2249611893.SGD","NLY","AIG","BC","BK4178","ARVN","EAT","ALB","BKNG","AGIO","BK","LU0971096721.USD","AEO","BBWI","ARCT","BOW","BRLT"],"gpt_icon":1},{"id":"2588204373","title":"Belite Bio Inc : Benchmark Raises Target Price to $187 From $132","url":"https://stock-news.laohu8.com/highlight/detail?id=2588204373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588204373?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:03","pubTimestamp":1764763391,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X90MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLTE","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://investors.belitebio.com","stockEarnings":[{"period":"1week","weight":-0.0671},{"period":"1month","weight":0.1404},{"period":"3month","weight":0.5015},{"period":"6month","weight":1.6303},{"period":"1year","weight":2.0981},{"period":"ytd","weight":0.0956}],"compareEarnings":[{"period":"1week","weight":-0.0128},{"period":"1month","weight":-0.0125},{"period":"3month","weight":0.0146},{"period":"6month","weight":0.0595},{"period":"1year","weight":0.1181},{"period":"ytd","weight":-0.0002}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.020711},{"month":2,"riseRate":0.75,"avgChangeRate":0.048724},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.036455},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.0153},{"month":5,"riseRate":0.75,"avgChangeRate":0.064631},{"month":6,"riseRate":0.25,"avgChangeRate":0.187208},{"month":7,"riseRate":1,"avgChangeRate":0.228556},{"month":8,"riseRate":0.25,"avgChangeRate":0.09699},{"month":9,"riseRate":0.5,"avgChangeRate":0.027284},{"month":10,"riseRate":0.75,"avgChangeRate":0.224047},{"month":11,"riseRate":0.75,"avgChangeRate":0.12408},{"month":12,"riseRate":0.5,"avgChangeRate":0.042173}],"exchange":"NASDAQ","name":"Belite Bio, Inc.","nameEN":"Belite Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Belite Bio, Inc.,BLTE,Belite Bio, Inc.股票,Belite Bio, Inc.股票老虎,Belite Bio, Inc.股票老虎国际,Belite Bio, Inc.行情,Belite Bio, Inc.股票行情,Belite Bio, Inc.股价,Belite Bio, Inc.股市,Belite Bio, Inc.股票价格,Belite Bio, Inc.股票交易,Belite Bio, Inc.股票购买,Belite Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Belite Bio, Inc.(BLTE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Belite Bio, Inc.(BLTE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction